Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul:121:102649.
doi: 10.1016/j.jaut.2021.102649. Epub 2021 May 1.

A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine

Haralampos M Moutsopoulos  1
Affiliations
Review

A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine

Haralampos M Moutsopoulos. J Autoimmun. 2021 Jul.

Abstract

Autoimmune and autoinflammatory rheumatic disorders (ARD) are treated with antimetabolites, calcineurin inhibitors and biologic agents either neutralizing cytokines [Tumor Necrosis Factor (TNF), Interleukin (IL)-1, IL-6, IL-17, B-cell activating factor] or being directed against B-cells (anti-CD-20), costimulatory molecules or JAK kinases. Similarly for the influenza or pneumococcal vaccines, there is limited data on the effectiveness of vaccination against SARS-CoV-2 infection and COVID-19 prevention for this susceptible patient population. Moreover, preliminary data from vaccinated organ transplanted, inflammatory bowel and connective tissue disease patients suggests only limited immunogenicity after the first vaccine dose, particularly in patients on immunosuppressive regimens. Herein a set of recommendations for the vaccination of immune suppressed patients with the SARS-CoV-2 vaccines is proposed aimed at achieving optimal vaccine benefit without interfering with disease activity status. Moreover, rare autoimmune adverse events related to vaccinations are discussed.

Keywords: Autoimmune rheumatic diseases; Immunosuppression; SARS-CoV-2; Vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Moutsopoulos H.M., Zampeli E. In: Immunology-Rheumatology in Questions. Moutsopoulos H.M., Zampeli E., editors. Springer-Nature publishers; 2021. Treatment and management of rheumatic diseases.
    1. Park J.K., Lee Y.J., Shin K., et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomized clinical trial. Ann. Rheum. Dis. 2018;77:898–904. - PMC - PubMed
    1. Kohmer N., Westhaus S., Rühl C., Ciesek S., Rabenau H.F. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. J. Clin. Virol. 2020;129:104480. - PMC - PubMed
    1. April 28, 2021. COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases Developed by the ACR COVID-19 Vaccine Clinical Guidance Task Force. Updated.
    1. Boyarsky B.J., Werbel W.A., Avery R.K., et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. J. Am. Med. Assoc. March 15, 2021 doi: 10.1001/jama.2021.4385. Published online. - DOI - PMC - PubMed

MeSH terms